Skedgel C. Wranik WD. Hu M. (2018). The relative importance of clinical, economics, patient values and feasibility criteria in cancer drug reimbursement in Canada: A revealed preferences analysis of recommendations of the pan-Canadian Oncology Drug Review 2011-2017. Pharmacoeconomics. First Online.
Wranik DW. Muir A. Hu M. (2017). Costs of productivity loss due to occupational cancer in Canada: estimation using claims data from Workers’ Compensation Boards. Health Economics Review. 7(1).
Wranik WD. Gambold L. Hanson N. Levy A. (2016) The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation? International Journal of Health Planning and Management. Online early view.